Alerts will be sent to your verified email
Verify Email
KABRADG
|
Kabra Drugs
|
JFL Life Sciences
|
Vineet Laboratories
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
36.01 % | 12.26 % | 6.82 % |
|
5yr average Equity Multiplier
|
-0.87 | 2.68 | 4.27 |
|
5yr Average Asset Turnover Ratio
|
0.0 | 0.93 | 1.52 |
|
5yr Avg Net Profit Margin
|
0.0 | 5.75 % | -4.28 % |
|
Price to Book
|
2.35 | 1.4 | 4.01 |
|
P/E
|
14.23 | 12.25 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
0.0 | 138.58 Days | 179.8 Days |
|
Inventory Days
|
0.0 | 96.42 Days | 114.74 Days |
|
Days Receivable
|
0.0 | 135.23 Days | 109.14 Days |
|
Days Payable
|
0.0 | 103.44 Days | 115.29 Days |
|
5yr Average Interest Coverage Ratio
|
-1068.45 | 4.03 | 1.29 |
|
5yr Avg ROCE
|
21.53 % | 17.72 % | -1.66 % |
|
5yr Avg Operating Profit Margin
|
0.0 | 10.31 % | -0.62 % |
|
5 yr average Debt to Equity
|
-1.45 | 0.9 | 1.24 |
|
5yr CAGR Net Profit
|
43.36 % | 50.43 % | n/a |
|
5yr Average Return on Assets
|
-21.34 % | 5.01 % | -2.52 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
0.0 | 67.47 % | 12.46 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | 0.0 | -23.5 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Kabra Drugs
|
JFL Life Sciences
|
Vineet Laboratories
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|